Abstract
Gosling plague (GP) is caused by goose parvovirus (GPV) gosling acute, subacute, and septic infectious diseases, commonly known as gosling plague. At present, the prevention and control of GP at home and abroad mainly adopts the method of immunizing female geese with attenuated vaccine. Goslings can be immunized, but there are still the phenomenon of dispersive virus and virulence reverse. It, therefore, is urgent to develop a new safe and effective vaccine. The recombinant avian pox virus vaccines rFPV-GoIFNγ, rFPV-GPV-VP3 and rFPV-GoIFNγ-VP3 were used to monitor their antibody levels and evaluate the protective mechanism of the vaccine in this study. This study lays a foundation for further in vivo testing of recombinant avian pox virus vaccine for goose parvovirus and provides a reference for the development of recombinant avian pox virus vaccine for other avian infectious diseases.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.